Abstract:Purpose: The enhanced relative biological effectiveness (RBE) at the end of the proton range might increase the risk of radiation-induced toxicities. This is of special concern for intracranial treatments where several critical organs at risk (OARs) surround the tumor. In the light of this, a retrospective analysis of dose-averaged linear energy transfer (LETd ) and RBE-weighted dose (DRBE ) distributions was conducted for three clinical cases with suspected treatment-related toxicities following intracranial proton therapy. Alternative treatment strategies aiming to reduce toxicity risks are also presented. Methods: The clinical single-field optimized (SFO) plans were recalculated for 81 error scenarios with a Monte Carlo dose engine. The fractionation DRBE was 1.8 Gy (RBE) in 28 or 30 fractions assuming a constant RBE of 1.1. Two LETd - and α/β-dependent variable RBE models were used for evaluation, including a sensitivity analysis of the α/β parameter. Resulting distributions of DRBE and LETd were analyzed together with normal tissue complication probabilities (NTCPs). Subsequently, four multi-field optimized (MFO) plans, with an additional beam and/or objectives penalizing protons stopping in OARs, were created to investigate the potential reduction of LETd , DRBE , and NTCP. Results: The two variable RBE models agreed well and predicted average RBE values around 1.3 in the toxicity volumes, resulting in an increased near-maximum DRBE of 7-11 Gy (RBE) compared to RBE = 1.1 in the nominal scenario. The corresponding NTCP estimates increased from 0.8%, 0.0%, and 3.7% (RBE = 1.1) to 15.5%, 1.8%, and 45.7% (Wedenberg RBE model) for the three patients, respectively. The MFO plans generally allowed for LETd , DRBE , and NTCP reductions in OARs, without compromising the target dose. Compared to the clinical SFO plans, the maximum reduction in the near-maximum LETd was 56%, 63%, and 72% in the OAR exhibiting the toxicity for the three patients, respectively. Conclusions: Although a direct causality between RBE and toxicity cannot be established here, high LETd and DRBE correlated spatially with the observed toxicities, whereas setup and range uncertainties had a minor impact. Individual factors, which might affect the patient-specific radiosensitivity, were however not included in these calculations. The MFO plans using both an additional beam and proton track-end objectives allowed the largest reductions in LETd , DRBE , and NTCP, and might be future tools for similar cases.

Secondary cancer risk assessments following the proton therapy of lung cancer as the functions of field characteristics and patient age

Assessment of secondary cancer risks within non-target organs during proton therapy for lung cancer: A Monte Carlo study

SU-FF-T-333: Monte Carlo Simulations Using Whole-Body Pediatric and Adult Phantoms as Virtual Patients to Assess Secondary Organ Doses in Proton Radiation Therapy

Secondary cancer risk in six anatomical sites when using PAT, IMPT, and VMAT/IMRT radiotherapy

Assessment of long-term risks of secondary cancer in paediatric patients with brain tumours after boron neutron capture therapy

MONTE CARLO SIMULATION OF OUT-OF-FIELD ORGAN DOSES AND CANCER RISK IN TANZANIA FOR RADIATION THERAPY OF UNILATERAL RETINOBLASTOMA USING A 60co UNIT

WE-C-AUD-05: Simulation of Neutron Dose Exposure for Pediatric Proton Therapy Patients Using Whole-Body Age-Dependent Voxel Phantoms

Radiation-Induced Toxicity Risks in Photon Versus Proton Therapy for Synchronous Bilateral Breast Cancer

Monte Carlo Simulation of Non-Target Organ Doses and Radiation-Induced Secondary Cancer Risk in Tanzania from Radiotherapy of Nasopharyngeal by Using Co-60 Source

The influence of daily imaging and target margin reduction on secondary cancer risk in image-guided and adaptive proton therapy

Complete patient exposure during paediatric brain cancer treatment for photon and proton therapy techniques including imaging procedures

Monte Carlo Study of Organ Doses and Related Risk for Cancer in Tanzania from Scattered Photons in Cervical Radiation Treatment Involving Co-60 Source.

MO‐E‐T‐617‐07: Simulation of Organ Specific Secondary Neutron Dose in Proton Beam Treatments

SU-GG-T-347: Methods to Calculate Organ Doses Due to Scattered Radiation From External Beam Radiation Treatment Using Various Patient Phantoms and Monte Carlo Simulations

In Vivo Mammary Tumourigenesis in the Sprague-Dawley Rat and Microdosimetric Correlates

Risk of Second Primary Cancers among Long-Term Survivors of Breast Cancer

EVALUATION OF SECONDARY DOSE AND CANCER RISK FOR OUT-OF-FIELD ORGAN IN ESOPHAGEAL CANCER IMRT IN A CHINESE HOSPITAL USING ATOM PHANTOM MEASUREMENTS.

Radiation Therapy for Stage IIA/B Seminoma: Modeling Secondary Cancer Risk for Protons and VMAT versus 3D Photons

Radiation-Related New Primary Solid Cancers in the Childhood Cancer Survivor Study: Comparative Radiation Dose Response and Modification of Treatment Effects

Spatial correlation of linear energy transfer and relative biological effectiveness with suspected treatment-related toxicities following proton therapy for intracranial tumors

Evaluation of IGRT-Induced Imaging Doses and Secondary Cancer Risk for SBRT Early Lung Cancer Patients in Silico Study